Medication info

Sitagliptin and Metformin Tablets 50/850 mg

Prescription medicationApproval withdrawn
Ingredient · strength
Sitagliptin Phosphate›Strength being verifiedMetformin Hydrochloride›Strength being verified
Manufacturer / importer
Aliko Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
28 tablets (14 tablets/PTP × 2)
Approval status
Approval withdrawn

MFDS item code 201507992 · Approved 2015.11.27

This product's status changed to Approval withdrawn on 2023.05.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one tablet of 50/500 mg twice daily. The dose may be increased to one tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Aliko Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes. It is administered along with dietary and exercise therapy and is effective for patients who have not experienced diabetes medication treatment or who have difficulty controlling blood sugar with monotherapy. Additionally, it can be used when monotherapy with metformin or sitagliptin is insufficient or as a substitute for combination therapy of both drugs. Patients may also receive this medication in conjunction with metformin when blood sugar control is challenging despite treatment with sulfonylureas or thiazolidinediones. If insulin and metformin therapy are not effective, this medication can enhance blood sugar control when used together. This medication helps to improve blood sugar management.

Dosage and Administration

Adult dosage

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one tablet of 50/500 mg twice daily. The dose may be increased to one tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication is used for diabetes treatment and contains two active ingredients. The first ingredient helps in controlling blood sugar, while the second ingredient promotes insulin secretion to reduce blood sugar levels. Before taking this medication, it is essential to verify if there have been any allergic reactions in the past. If symptoms such as skin rash, hives, or difficulty breathing occur, discontinue use immediately and consult a doctor. Severe pancreatic disease known as acute pancreatitis may occur, so it is important to inform healthcare personnel immediately if symptoms include abdominal pain, vomiting, or nausea during treatment. Patients with severely impaired kidney function or specific health conditions such as severe infection, dehydration, or heart failure should not take this medication. Before tests involving radiologic contrast agents, the use of this medication should be temporarily suspended, and it should be restarted only after confirming normal kidney function post-examination. It is advisable for pregnant or potentially pregnant women, as well as nursing mothers, to refrain from using this medication. This medication may cause hypoglycemia; hence, blood sugar levels should be closely monitored in cases of irregular meals, excessive exercise, or concomitant use with other hypoglycemic agents. During treatment, gastrointestinal symptoms such as diarrhea, nausea, vomiting, and headache can occur, and severe joint pain or skin blistering may also arise as adverse reactions. Alcohol consumption may increase the risk of side effects from this medication, so it is recommended to avoid drinking while on treatment. Patients taking this medication should have regular blood tests and kidney function evaluations, including periodic checks of vitamin B12 levels. In cases of overdose, individuals should visit a medical institution immediately for appropriate treatment, as some ingredients may be removed through hemodialysis. Patients on this medication should be cautious of hypoglycemic symptoms while driving or operating machinery and may need to consult their doctor for dosage adjustments.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
Show 24 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe joint pain with disability
  • blistering variant of pemphigus
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • gastrointestinal disorders
  • itchiness
  • dermatitis
  • weight loss
  • hypoglycemic adverse reactions
  • severe hypoglycemia
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent exposure to air or moisture, and keep it at a temperature between 1 and 30 degrees Celsius. This will help maintain the medication's efficacy and ensure safe use.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

28 tablets (14 tablets/PTP × 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.